240 related articles for article (PubMed ID: 10782864)
1. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.
Pulaski BA; Clements VK; Pipeling MR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2000 Apr; 49(1):34-45. PubMed ID: 10782864
[TBL] [Abstract][Full Text] [Related]
2. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
Ilkovitch D; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
[TBL] [Abstract][Full Text] [Related]
3. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
4. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.
Pulaski BA; Ostrand-Rosenberg S
Cancer Res; 1998 Apr; 58(7):1486-93. PubMed ID: 9537252
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines.
Ostrand-Rosenberg S; Pulaski BA; Armstrong TD; Clements VK
Adv Exp Med Biol; 1998; 451():259-64. PubMed ID: 10026883
[No Abstract] [Full Text] [Related]
6. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
[TBL] [Abstract][Full Text] [Related]
7. Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferon gamma (IFN gamma) are recognised by T cells while resisting destruction by natural killer (NK) cells.
Zier KS; Gansbacher B
Eur J Cancer; 1996 Jul; 32A(8):1408-12. PubMed ID: 8869107
[TBL] [Abstract][Full Text] [Related]
8. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
Dezfouli S; Hatzinisiriou I; Ralph SJ
Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
[TBL] [Abstract][Full Text] [Related]
9. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
10. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma.
Wu RS; Kobie JJ; Besselsen DG; Fong TC; Mack VD; McEarchern JA; Akporiaye ET
Cancer Immunol Immunother; 2001 Jul; 50(5):229-40. PubMed ID: 11499806
[TBL] [Abstract][Full Text] [Related]
12. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
13. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
Kim TS; Xu WS; Sun T; Cohen EP
Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer.
Sabel MS; Su G; Griffith KA; Chang AE
Breast Cancer Res Treat; 2010 Jul; 122(2):325-36. PubMed ID: 19802695
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-12 neutralization alters lung inflammation and leukocyte expression of CD80, CD86, and major histocompatibility complex class II in mice infected with Histoplasma capsulatum.
Cain JA; Deepe GS
Infect Immun; 2000 Apr; 68(4):2069-76. PubMed ID: 10722603
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
17. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
20. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy.
Dissanayake SK; Thompson JA; Bosch JJ; Clements VK; Chen PW; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2004 Mar; 64(5):1867-74. PubMed ID: 14996751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
